scholarly journals Radiation Therapy for Bone Metastases from Hepatocellular Carcinoma: Effect of Radiation Dose Escalation

2011 ◽  
Vol 29 (2) ◽  
pp. 63 ◽  
Author(s):  
Tae Gyu Kim ◽  
Hee Chul Park ◽  
Do Hoon Lim ◽  
Cheol Jin Kim ◽  
Hye Bin Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Radiation Dose ◽  
Bone Metastases ◽  
Dose Escalation

scholarly journals Radiation Therapy and Palliative Care Prolongs the Survival of Hepatocellular Carcinoma Patients with Bone Metastases

2016 ◽  
Vol 55 (9) ◽  
pp. 1077-1083 ◽  
Author(s):  
Masakuni Sakaguchi ◽  
Toshiya Maebayashi ◽  
Takuya Aizawa ◽  
Naoya Ishibashi ◽  
Shoko Fukushima ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Palliative Care ◽  
Radiation Therapy ◽  
Bone Metastases

Radiation dose escalation using intensity modulated radiation therapy for gross unresected node-positive endometrial cancer

2014 ◽  
Vol 4 (2) ◽  
pp. 90-98 ◽  
Author(s):  
Kanokpis Townamchai ◽  
Philip D. Poorvu ◽  
Antonio L. Damato ◽  
Rebecca DeMaria ◽  
Larissa J. Lee ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Endometrial Cancer ◽  
Radiation Dose ◽  
Dose Escalation ◽  
Intensity Modulated Radiation Therapy ◽  
Intensity Modulated ◽  
Node Positive

scholarly journals Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1612
Author(s):  
Yeona Cho ◽  
Jun Won Kim ◽  
Ja Kyung Kim ◽  
Kwan Sik Lee ◽  
Jung Il Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Dose ◽  
Phase I ◽  
Dose Level ◽  
Dose Escalation ◽  
Level 3 ◽  
Level 1 ◽  
Grade 3 ◽  
Dose Limiting Toxicity

Concurrent intra-arterial chemotherapy and radiotherapy (iA-CCRT) can increase the response rate in hepatocellular carcinoma (HCC), but may cause a higher toxicity. We conducted this Phase I study to investigate the dose-limiting toxicity of iA-CCRT for HCC. In total, 52.5 Gy in 25 fractions was prescribed as planning target volume (PTV) 1 at dose level 1. The dose escalation was 0.2 Gy per fraction and up to 2.5 Gy, with 62.5 Gy at level 3. Concurrent intra-arterial 5-fluorouracil was administered during the first and fifth weeks of radiotherapy (RT). Toxicities were graded using the Common Toxicity Criteria for Adverse Events, version 4.0. Results: Seventeen patients with HCC were analyzed: four at dose level 1, 6 at level 2, and 7 at level 3. The mean irradiated dose administered to the uninvolved liver at each dose level was 21.3, 21.6, and 18.2 Gy, respectively. There was no grade ≥3 gastrointestinal toxicity; two patients experienced grade 3 hyperbilirubinemia. All patients had Child-Pugh class A disease, but 3 patients developed class B disease after iA-CCRT. During a median follow-up of 13 months, the median progression-free survival (PFS) and overall survival (OS) were 10 and 22 months, respectively. Patients treated at dose level 3 showed improved PFS and OS. Conclusions: Radiation dose escalation of iA-CCRT did not cause any significant toxicities in patients with advanced HCC. Further large-scale studies with long-term follow-up are needed to determine the efficacy and feasibility of higher doses of iA-CCRT.

Sign in / Sign up

Export Citation Format

Share Document